Oxford University creates its 200th spinout company PhishAR
28 October 2020
Oxford University, through its research commercialisation arm Oxford University Innovation, has created its 200th company based on academic research, PhishAR.
Global clinical trials of COVID-19 vaccine resume
26 October 2020
The Food and Drug Administration (FDA) has today authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford coronavirus vaccine in the USA following the trials restarting in the UK, Brazil, South Africa and Japan.
Medium-term impact of COVID-19 revealed in new study
21 October 2020
Initial findings from a study looking at the longer-term impact of COVID-19 has found that a large proportion COVID-19 patients discharged from hospital were still experiencing symptoms of breathlessness, fatigue, anxiety and depression two to three months after contracting the virus.
Oxford scientists develop extremely rapid diagnostic test for Covid-19
21 October 2020
Scientists from Oxford University’s Department of Physics have developed an extremely rapid diagnostic test that detects and identifies viruses in less than five minutes.
Three Oxford researchers win top UKRI Future Leaders Fellowships
21 October 2020
Three Oxford academics have today been awarded major financial backing with UKRI Future Leaders Fellowships – for their ‘world-class research and innovation’ into space flight, high risk pregnancy and finding answers to chaotic public out-sourcing.
‘Junk’ DNA could be rewiring our brains
21 October 2020
New partnership with King Abdulaziz University aims to revolutionise drug discovery using artificial intelligence
2 October 2020
The University of Oxford and King Abdulaziz University (KAU) have partnered to create a new Centre for Artificial Intelligence and Precision Medicine.
Comparison of five tests used to detect COVID-19 antibodies shows Siemens and Oxford assays met regulatory targets
2 October 2020
New research shows that, in a head-to-head comparison of five tests used to detect COVID-19 antibodies (known as ‘immunoassays’), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results. The study is published in The Lancet Infectious Diseases.
Global consortium launches new study into long-term effects of COVID-19
14 September 2020
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), based at Oxford University, in collaboration with Dr Janet Scott, of the MRC-University of Glasgow’s Centre for Virus Research, has launched a longitudinal observational study to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19. The researchers are inviting hospitals and healthcare sites worldwide to join this new study.
Persistent immune memory of COVID-19 found in recovered patient T cells
4 September 2020
Oxford University researchers have found that natural infection with COVID-19 produces a robust T cell response, including inducing T cell ‘memory’ to potentially fight future infections.
Five years at the top: Oxford retains first place in World University Rankings
4 September 2020
Oxford University has topped the THE World University Rankings for a fifth consecutive year.
Development of Oxford COVID-19 vaccine expands into US Phase III clinical trial
4 September 2020
A new arm of the ongoing global clinical trials of the ChAdOx1 nCoV-19 vaccine led by AstraZeneca has launched in the US to assess safety, efficacy and immunogenicity of the vaccine for the prevention of COVID-19.
Four Oxford academics honoured by the Royal Society
5 August 2020
Four researchers from Oxford University have today received prestigious medals and prizes from the Royal Society in recognition of their outstanding contributions to science and medicine.
New study reveals Oxford coronavirus vaccine produces strong immune response
31 July 2020
A team of scientists at Oxford University’s Jenner Institute and Oxford Vaccine Group has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
Value of lipocalin 2 as a potential biomarker for bacterial meningitis
24 July 2020
A team from OUCRU led by Le Van Tan, Hospital for Tropical Diseases, Vietnam, and Benedikt Kessler at the Target Discovery Institute at the University of Oxford showed that lipocalin 2 is a sensitive and specific biomarker for discriminating bacterial meningitis from a broad spectrum of other brain infections, and outperforms routine CSF markers such as leukocytes, glucose, protein and lactate.
Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19
17 June 2020
In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK.
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
5 June 2020
A new statement has been released from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine.
Expanding the immune system's arsenal to fend off viruses and cancer cells
13 May 2020
Cytotoxic T lymphocytes (CTLs) kill infected and cancerous cells. Mike Dustin's team at the Kennedy Institute of Rheumatology, together with Roman Fischer and Benedikt Kessler from the Target Discovery Institute, NDM, detected transfer of cytotoxic multiprotein complexes from CTLs to target cells, termed supramolecular attack particles (SMAPs). SMAPs were rapidly released from CTLs and were autonomously cytotoxic.
Volunteer for COVID-19 studies at Oxford
12 May 2020
We have a range of studies taking place at the moment, below are listed those that are still open for participants to take part in.
Six Oxford professors honoured by the Royal Society
1 May 2020
Six Oxford University academics have been elected to the prestigious Fellowship of the Royal Society.